121 related articles for article (PubMed ID: 30850872)
1.
Toriihara A; Duan H; Thompson HM; Park S; Hatami N; Baratto L; Fan AC; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1518-1523. PubMed ID: 30850872
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
3. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
[TBL] [Abstract][Full Text] [Related]
6. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
7. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract][Full Text] [Related]
10. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [
Dong Y; Wei Y; Chen G; Huang Y; Song P; Liu S; Zheng J; Cheng M; Yuan S
Mol Imaging Biol; 2019 Feb; 21(1):175-182. PubMed ID: 29869060
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
[TBL] [Abstract][Full Text] [Related]
17. Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors.
Gündoğan C; Çermik TF; Erkan E; Yardimci AH; Behzatoğlu K; Tatar G; Okçu O; Toktaş MG
Nucl Med Commun; 2018 Dec; 39(12):1174-1182. PubMed ID: 30234688
[TBL] [Abstract][Full Text] [Related]
18. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
19. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
[TBL] [Abstract][Full Text] [Related]
20. [
Zheng S; Chen Z; Huang C; Chen Y; Miao W
Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]